Marshall Wace
XERS icon

Marshall Wace’s Xeris Biopharma Holdings XERS Stock Holding History

Marshall Wace’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-31,899
Closed -$225K – 2106
2019
Q4 		$225K Buy
+31,899
New +$263K ﹤0.01% 1319
2019
Q2 		– Sell
-24,451
Closed -$245K – 1909
2019
Q1 		$245K Buy
+24,451
New +$313K ﹤0.01% 1299

Other funds holding XERS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Marshall Wace's XERS Position: Q1 2020 in Review

Marshall Wace sold out of Xeris Biopharma Holdings (XERS) in Q1 2020, closing a stake of 31,899 shares — an estimated $225K sold.

Marshall Wace first reported a position in XERS in Q1 2019 and held it in 2 quarters. The position peaked at $245K in Q1 2019. 67 funds tracked by Wall St. Rank hold XERS as of Q1 2020.

  • Marshall Wace reported no remaining Xeris Biopharma Holdings position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace sold 31,899 Xeris Biopharma Holdings shares in Q1 2020, an estimated $225K.
  • Marshall Wace first reported a position in Xeris Biopharma Holdings in Q1 2019 and held it in 2 quarters.
  • Marshall Wace's Xeris Biopharma Holdings position peaked at $245K in Q1 2019.
  • 67 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2020.

Based on Marshall Wace's 13F filing for Q1 2020, filed 15 May 2020.